Recognizing the need for effective and non-invasive treatments, Optimum TMS has become a trusted destination for patients seeking TMS therapy for depression. With countless success stories, approximately 70% of patients have reported a significant reduction in symptoms, while nearly 50% achieve full remission.
To qualify for TMS therapy, patients must have tried at least two anti-depressant medications, undergone talk therapy, and experienced persistent depression. TMS offers a medication-free and non-invasive alternative that requires only 20 minutes per day, minimizing inconvenience while maximizing efficacy. Moreover, TMS treatment has been shown to have minimal side effects, ensuring a comfortable and safe experience.
Optimum TMS understands the financial considerations associated with these treatment options and is committed to helping patients navigate insurance coverage and potential out-of-pocket expenses. With TMS being covered by most insurance companies, patients who may have hesitated due to cost can rest assured that it may be more affordable than anticipated. Optimum TMS offers their expertise in working with patients' insurance providers to determine coverage and explore financial aid options, such as CareCredit and in-house financing/payment arrangements.
Optimum TMS takes pride in providing patients with the highest quality of care and offers two FDA-cleared TMS devices: Brainsway Deep TMS and NeuroStar Advanced Therapy TMS. Both devices have demonstrated their effectiveness as non-drug treatment options for depression, offering patients a comprehensive range of choices tailored to meet their individual needs.
About Optimum TMS:
Optimum TMS is a renowned provider of TMS therapy and Spravato® treatment for depression, devoted to transforming lives through innovative mental health solutions. Committed to making TMS accessible to individuals seeking alternative treatment options, Optimum TMS offers expertise, affordability, and personalized care that elevates mental health outcomes.
This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.
